Retatrutide is a next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It is studied for its potential to produce synergistic metabolic effects by combining three distinct hormonal pathways — reducing appetite, improving insulin sensitivity, and increasing energy expenditure — making it a subject of significant interest in preclinical obesity and metabolic research.
Retatrutide
$125.00Price
- Triple receptor agonism (GLP-1 + GIP + Glucagon) for broad-spectrum metabolic research
- Preclinical research models support significant reductions in fat mass through triple pathway activation
- Studied for improvements in insulin sensitivity and glycaemic regulation across multiple metabolic pathways
- Increases energy expenditure through glucagon receptor component — a key differentiator from dual agonists
- Long-acting acylation chemistry supports extended dosing intervals in research protocols
